Article
Oncology
Domenica Lorusso, Sandro Pignata, Stefano Tamberi, Giorgia Mangili, Alessandra Bologna, Milena Sabrina Nicoloso, Serena Giolitto, Vanda Salutari, Mara Mantero, Carmela Pisano, Alice Bergamini, Lucia Musacchio, Dominique Ronzulli, Francesco Raspagliesi, Giovanni Scambia
Summary: This open-label phase II clinical trial evaluated the antitumor activity and safety of trabectedin in patients with advanced ovarian or uterine carcinosarcomas. The results showed that trabectedin conferred modest but clinically meaningful benefit to patients with advanced ovarian or uterine carcinosarcomas, although it did not meet the prespecified activity criteria. The toxicity profile was similar to that previously reported for the drug.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Mingming Zhang, Dongchang Yang, Lu Li, Lin Liu, Ting Wang, Tao Liu, Lei Li, Yanrong Liu
Summary: Hepatic carcinosarcoma (HCS) is a tumor that contains cancer from the epithelium and sarcoma from mesenchymal tissue. Through the process of epithelial-mesenchymal transition (EMT), cancer cells acquire a mesenchymal phenotype, while losing epithelial properties. This study suggests that ZEB1 plays an important role in the development of HCS and is associated with EMT.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Zachery Branham, Ashley D. Fox, Asad Ullah, Nikhil G. Patel, Martha Terris, Jigarkumar Parikh
Summary: This case report describes a rare case of adrenal cortical carcinosarcoma in a 78-year-old female patient. The unique histology of this malignancy, with both carcinomatous and sarcomatous components, presents a diagnostic challenge for clinicians. The study emphasizes the importance of considering adrenal carcinosarcomas in the differential diagnosis of retroperitoneal masses.
Article
Oncology
Jennifer McEachron, Yi-Ju Chen, Nancy Zhou, Johnny Kao, Constantine Gorelick, Marguax J. Kanis, Yi-Chun Lee
Summary: This study evaluated the impact of different adjuvant treatment modalities on survival and recurrence patterns in uterine carcinosarcoma patients. The results showed that chemoradiation was associated with improved survival and disease control, particularly in stage III patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Osamu Gotoh, Kazuma Kiyotani, Tomohiro Chiba, Yuko Sugiyama, Yutaka Takazawa, Kensaku Nemoto, Kazuyoshi Kato, Norio Tanaka, Hidetaka Nomura, Kosei Hasegawa, Keiichi Fujiwara, Shiro Takamatsu, Noriomi Matsumura, Tetsuo Noda, Seiichi Mori
Summary: The study investigated the influence of immune cells infiltrating carcinosarcoma of the uterus or ovary to better understand the immunological status of gynecological CS. Different molecular subtypes of CS exhibited distinct tumor immune microenvironments and patient outcomes, highlighting the potential clinical utility of tumor immune microenvironmental analyses above genomic aberration subtype classification.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Ayumi Saito, Tadaaki Nishikawa, Hiroshi Yoshida, Chiharu Mizoguchi, Rui Kitadai, Kasumi Yamamoto, Shu Yazaki, Yuki Kojima, Mitsuya Ishikawa, Tomoyasu Kato, Kan Yonemori
Summary: This study investigated the expression and clinical significance of folate receptor alpha (FRα) in uterine carcinosarcoma (UCS) and ovarian carcinosarcoma (OCS). The results showed that FRα was universally expressed in all patients, but it was not significantly associated with clinicopathological features or prognosis. However, FRα-targeted therapies may have potential therapeutic effects for gynecologic carcinosarcoma.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Dermatology
Thomas Weiland, Birgit Sadoghi, Prisca Pondorfer, Peter Kiss, Iva Brcic, Dietmar Thurnher
Summary: This article reports a rare case of trichoblastic carcinosarcoma developed on a preexisting trichoblastoma in the neck, presenting aggressive and recurrent behavior. Despite successful surgical treatments, the tumor recurred three times within 4 years. Copy number variation analysis of the preexisting tumor and two recurrences revealed the same entity and additional chromosomal aberrations.
JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
Tiffany Y. Sia, Sushmita B. Gordhandas, Ozge Birsoy, Yelena Kemel, Anna Maio, Erin Salo-Mullen, Margaret Sheehan, Martee L. Hensley, Maria Rubinstein, Vicky Makker, Rachel N. Grisham, Roisin E. O'Cearbhaill, Kara Long Roche, Jennifer J. Mueller, Mario M. Leitao Jr, Yukio Sonoda, Dennis S. Chi, Nadeem R. Abu-Rustum, Michael F. Berger, Lora H. Ellenson, Alicia Latham, Zsofia Stadler, Kenneth Offit, Carol Aghajanian, Britta Weigelt, Diana Mandelker, Ying L. Liu
Summary: This study describes the prevalence of germline pathogenic variants (gPVs) in endometrial and ovarian carcinosarcomas and determines if gPVs are drivers of carcinosarcoma. The results showed that out of 216 patients, 29 patients (13%) had 33 gPVs, with 61% of gPVs showing biallelic loss in tumors. The study also found that gPVs in genes affecting homologous recombination or Lynch-associated mismatch repair exhibited biallelic inactivation within tumors. These findings suggest that gPVs may be drivers of gynecologic carcinosarcoma.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Oncology
Nuhad K. Ibrahim
Summary: The epothilone drug class, including ixabepilone, has shown efficacy and safety in the treatment of metastatic breast cancer, demonstrating improved progression-free survival and overall response rates in patients who have progressed during chemotherapy. Additionally, ixabepilone's clinical benefit in special populations has been characterized, with evidence supporting its use in specific patient groups such as those with triple-negative breast cancer. Dose reductions do not appear to impact the efficacy of ixabepilone, making it a valuable option for individualized treatment plans in patients with unmet needs.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Dennis Mauricio, Stefania Bellone, Levent Mutlu, Blair McNamara, Diego D. Manavella, Cem Demirkiran, Miguel Skyler Z. Verzosa, Natalia Buza, Pei Hui, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Margherita Zipponi, Gary Altwerger, Elena Ratner, Gloria S. Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin
Summary: This study compared the efficacy of a novel HER2/neu-targeting antibody-drug conjugate, DS-8201a, to an ADC isotype control, MAAA-9199, against primary uterine and ovarian carcinosarcomas in vitro and in vivo. The results showed that DS-8201a was highly effective against carcinosarcoma cell lines with 3+ HER2/neu expression, but not against 0 HER2/neu cell lines. However, DS-8201a could induce efficient bystander killing of 0 HER2/neu tumor cells when mixed with 3+ HER2/neu cells. In vivo studies confirmed the superior efficacy of DS-8201a in HER2/neu-expressing carcinosarcoma xenografts.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Myriam Gracia, Yusuf Yildirim, Ronalds Macuks, Rosanna Mancari, Patriciu Achimas-Cadariu, Stephan Polterauer, Sara Iacoponi, Ignacio Zapardiel, SARCUT Study Grp
Summary: Uterine carcinosarcoma is a rare disease that accounts for less than 5% of uterine malignancies but contributes to approximately 16% of uterine cancer-related deaths. In this study, prognostic factors, such as incomplete cytoreduction, advanced disease stage, presence of residual tumor, extrauterine disease, and tumor size, were found to significantly impact disease-free survival and overall survival among patients with uterine carcinosarcoma.
Article
Oncology
Clemence Romeo, Olivia Le Saux, Margaux Jacobs, Florence Joly, Gwenael Ferron, Laure Favier, Jean-David Fumet, Nicolas Isambert, Pierre-Emmanuel Colombo, Renaud Sabatier, Ludovic Bastide, Amandine Charreton, Mojgan Devouassoux-Shisheboran, Witold Gertych, Coraline Dubot, Diana Bello Roufai, Guillaume Bataillon, Dominique Berton, Elsa Kalbacher, Patricia Pautier, Christophe Pomel, Caroline Cornou, Isabelle Treilleux, Audrey Lardy-Cleaud, Isabelle Ray-Coquard
Summary: Gynecologic carcinosarcomas are rare and aggressive diseases with a poor prognosis. This multicentric cohort study using data from the French National Rare Malignant Gynecological Tumors (TMRG) network found that adjuvant chemotherapy has a positive impact on survival in all stages of carcinosarcomas, and platinum-based combination therapy is important for the treatment of relapse.
Article
Biochemistry & Molecular Biology
Giovanni Corso, Monica Marabelli, Mariarosaria Calvello, Sara Gandini, Matilde Risti, Irene Feroce, Sara Mannucci, Antonia Girardi, Alessandra Margherita De Scalzi, Francesca Magnoni, Elena Marino, Loris Bernard, Paolo Veronesi, Elena Guerini-Rocco, Massimo Barberis, Aliana Guerrieri-Gonzaga, Bernardo Bonanni
Summary: Metaplastic breast cancer (MpBC), a rare and aggressive subtype, has been linked to BRCA1 gene involvement. A retrospective study found that 65% of MpBC patients harbored a pathogenic variant (PV), with the majority in BRCA1. BRCA carriers had a significantly higher risk of developing MpBC compared to other breast cancer patients tested for BRCA genes. The prevalence of MpBCs was significantly different between BRCA1 and BRCA2 carriers. Further studies are needed to elucidate the role of BRCA1 and explore other genes' implication in MpBC predisposition.
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Article
Surgery
Logan Erz, Brandon Smith, Brandon Larson, Truong Ma
Summary: Carcinosarcoma, also known as MMMT, is a rare and aggressive malignant tumor with a poor prognosis. Surgical debulking and systemic chemotherapy are the main treatment modalities. Here we present a unique case of primary peritoneal carcinosarcoma in a 48-year-old Amish female and discuss its work-up and surgical management.
FRONTIERS IN SURGERY
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Ritesh R. Suthar, Archi Agrawal, Munita Bal, Nilendu Purandare, Sneha Shah, Ameya Puranik, Venkatesh Rangarajan
Summary: A rare malignancy of carcinosarcoma gallbladder with osteosarcomatous differentiation was reported in a middle-aged woman, showing intensely FDG-avid mass in the gallbladder with calcification due to the presence of osteoid.
CLINICAL NUCLEAR MEDICINE
(2021)
Review
Oncology
Nicole Birrer, Carolina Chinchilla, Marcela Del Carmen, Don S. Dizon
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2018)
Article
Oncology
Sarah E. Pesek, Heather M. King, Susan Koelliker, Christina Raker, David Edmonson, Don S. Dizon, Jennifer Gass
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2018)
Article
Oncology
Areej El-Jawahri, Sarah R. Fishman, Julie Vanderklish, Don S. Dizon, Nicole Pensak, Lara Traeger, Joseph A. Greer, Elyse R. Park, Netana Markovitz, Lauren Waldman, Chrisa Hunnewell, Meredith Saylor, Jessica Driscoll, Zhigang Li, Thomas R. Spitzer, Steven McAfee, Yi-Bin Chen, Jennifer S. Temel
Article
Oncology
Carol Aghajanian, Virginia Filiaci, Don S. Dizon, Jay W. Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu S. Tewari, David P. Bender, David M. O'Malley, Ashley Stuckey, Jianjiong Gao, Fanny Dao, Robert A. Soslow, Heather A. Lankes, Kathleen Moore, Douglas A. Levine
GYNECOLOGIC ONCOLOGY
(2018)
Meeting Abstract
Oncology
Belle Hadewijch de Rooij, Elyse R. Park, Giselle Katiria Perez, Julia Rabin, Katharine M. Quain, Don S. Dizon, Kathryn E. Post, Garrett Chinn, Allison McDonough, Rachel Jimenez, Lonneke V. van de Poll-Franse, Jeffrey M. Peppercorn
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Belle Hadewijch de Rooij, Teresa Hagan, Kathryn E. Post, Jane M. Flanagan, Jeffrey M. Peppercorn, Don S. Dizon
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Article
Oncology
Don S. Dizon, Dora Dias-Santagata, Amy Bregar, Laura Sullivan, Jennifer Filipi, Elizabeth DiTavi, Lucy Miller, Leif Ellisen, Michael Birrer, Marcela DelCarmen
Meeting Abstract
Oncology
Jeffrey M. Peppercorn, Katharine M. Quain, Karen Sepucha, Don S. Dizon, Beverly Moy, Laura Spring, Therese Marie Mulvey, Jennifer Adrienne Shin, Giselle Katiria Perez
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Emeline Aviki, Marina Stasenko, Sarah E. Dilley, William P. Tew, Don S. Dizon, Peter Bach, Carol L. Brown
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Review
Surgery
Mary Lopresti, Tina Rizack, Don S. Dizon
Meeting Abstract
Hematology
Areej R. El-Jawahri, Sarah Fishman, Julie Vanderklish, Lara Traeger, Don Dizon, Thomas R. Spitzer, Steven L. McAfee, Zachariah DeFilipp, Yi-Bin Chen, Jennifer Temel
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2018)
Article
Oncology
Jennifer S. Gass, Michaela Onstad, Sarah Pesek, Kristin Rojas, Sara Fogarty, Ashley Stuckey, Christina Raker, Don S. Dizon
ANNALS OF SURGICAL ONCOLOGY
(2017)
Article
Oncology
Eleonora P. Preti, Fabio Landoni, Nicoletta Colombo, Don S. Dizon
Letter
Oncology
C. Dittrich, F. Stiefel, A. Kiss, D. S. Dizon
ANNALS OF ONCOLOGY
(2017)
Article
Oncology
Jennifer Y. Wo, Lorraine C. Drapek, Andrzej Niemierko, Brenda Silvia, Bridget N. Noe, Andrea L. Russo, David T. Miyamoto, Theodore S. Hong, Jason A. Efstathiou, Anthony L. Zietman, Don S. Dizon
PRACTICAL RADIATION ONCOLOGY
(2018)